Leveraging Click Chemistry: An Approach to Developing Small Molecule Inhibitors to Suppress the Spread of Breast Cancer
2024
- 6Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage6
- Abstract Views6
Artifact Description
One in eight females in the United States will develop breast cancer within their lifetime. With the occurrence of metastasis, survival rates drastically decline as much as 70%. Prior research has confirmed that overexpression of an inflammatory cytokine (IC) promotes metastasis via the activation of the JAK/STAT signaling pathway, suggesting that the IC is a promising target for repression by a small molecule inhibitor (SMI). Initial computational screenings identified quinoline-cored SMI-26 as a promising lead which is currently being optimized. A computational approach using UCFS Chimera and AutoDock Vina was used to design new analogs with increased inhibition of the IC as well as more favorable pharmacokinetic properties. Due to the high conjugation of the quinoline core, solubility was the main target for the designing of the analogs. To accomplish the synthesis of these improved analogs, a library of diverse and elaborate azides were synthesized via diazotransfers. From this, the azides were subjected to the triazole-forming azide-alkyne cycloaddition, a form of click chemistry enabling the addition of various substituents to a compound in an assembly-line fashion. The addition of heterocycles with hydrogen bonding capabilities to the azides at the is predicted to enhance the effectiveness and safety of the compound as a pharmaceutical drug.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know